Participated in Mironid's Series A extension, raising $35M to date for ADPKD small-molecule therapeutics.
SEP 2023
Mironid is a biopharmaceutical company developing novel small-molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases, focusing on innovative scientific approaches to address high unmet medical needs
Mironid is a biopharmaceutical company developing novel small-molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases, focusing on innovative scientific approaches to address high unmet medical needs.